Dimerix Limited (AU:DXB) has released an update.
Dimerix Limited is set to host a webinar on November 6, 2024, to discuss initial findings from Project PARASOL, which aims to advance FSGS treatment by exploring new biomarker-based endpoints. This initiative could potentially accelerate approval pathways for FSGS therapies, addressing a significant need in the market with no currently approved treatments. The webinar is expected to attract interest from stakeholders keen on the latest developments in kidney disease research.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- No Resolution Between Paramount Global (NASDAQ:PARA) and Nielsen
- Ford (NYSE:F) Enters Mustang Mach-E in Road Rally
- Concerns Growing Over Intel (NASDAQ:INTC) Battlemage Line
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
